OBJECTIVES: Sternal wound dehiscence (SWD) after cardiac surgery is a rare but serious condition associated with considerable costs and morbidity. We sought to evaluate the results of the introduction of vacuum-assisted closure (VAC) therapy in the management of sternal wound dehiscence, compared with those of previous conventional treatments.
INTRODUCTION
Median sternotomy wound complications include a broad spectrum of conditions, ranging from sterile wound dehiscence to mediastinitis. These are serious, life-threatening complications with a considerable reported incidence (0.3-9.7% depending on classification criteria) [1] [2] [3] and a high mortality rate (14-47%) when a mediastinal infection has developed [3] . Furthermore, associated morbidity, prolonged hospital stay and need for repeated surgical procedures lead to a significant increase in the cost of care [3, 4] .
Depending on the severity of sternal wound complication (SWC), different treatment strategies have been described over the past decades: open packing, closed irrigation and omental or muscular flap [1, 2, 5] . In 1997, Argenta and Morykwas [6] introduced a new method for wound treatment: vacuum-assisted closure (VAC) therapy. This technique entails creating a controlled subatmospheric pressure environment that promotes wound healing by removing chronic oedema, increasing localized blood flow and enhancing formation of granulation tissue.
We reviewed our institutional experience with VAC therapy in order to evaluate its impact on the outcomes of sternal wound dehiscences (SWDs) and its associated costs.
MATERIALS AND METHODS

Definitions
We classified sternal wound complications as follows:
(i) non-infected SWD: median sternotomy wound breakdown in the absence of clinical or microbiological evidence of infection.
(ii) Infected SWD: clinical and microbiological evidence of infection ( patient has organisms cultured from wound tissue). These two types of SWD are further divided into: (a) superficial-when only cutaneous and/or subcutaneous tissue are involved and (b) deep-when the dehiscence reaches the sternal surface and there is sternal instability without opening the mediastinal space and no evidence of mediastinitis. (iii) Mediastinitis is identified according to the US Centers for Disease Control and Prevention (CDC) definition [7] ( Table 1) . Osteomyelitis (diagnosed according to CDC definition) is considered a deep-infected SWD.
Treatment
Perioperative management was previously described by our group [8] . In all patients, at presentation, culture swabs were collected from the wound; then, under sterile conditions, we performed an extensive debridement of all non-viable tissue and an accurate cleansing with sodium hypochlorite and hydrogen peroxide; dehiscence extension and sternal stability were established at this time.
Conventional treatment consisted of repeated (once or twice a day) wound irrigation with disinfectant and antibiotic solution, debridement and covering with sterile gauzes; wound healing occurred by secondary intention or surgical revision.
The VAC therapy was carried out using the KCI VAC® therapy device. The system is made of a polyurethane ether foam dressing with a pore size of 400-600 µm to provide uniform distribution of negative pressure; the foam is carefully shaped to fit with the wound geometry and placed into the wound. The wound site is then covered with an adhesive sterile drape creating a closed compartment in which a controlled negative pressure is obtained through a vacuum pump connected to the foam by a rigid tube. The effluent wound fluid is collected into a replaceable canister. Negative pressures used ranged from −75 to −150 mmHg. We used a standard foam in non-infected SWD and a silver foam in infected SWD. The VAC therapy was replaced three times a week for non-infected SWD and twice a week for infected SWD. Criteria for VAC removal were negative bacterial culture, absence of fever, falling C-reactive protein levels and clinically healthy granulating wound. Sternal wounds were then allowed to close by secondary intention or closed surgically depending on their size. All infected SWD were treated with targeted antibiotic therapy, based on culture and antibiotic sensitivity results.
Patients
Ethics approval was granted by the University of Padova Research Ethics Review Board, and individual patient consent was obtained. Between January 2002 and June 2012, 7148 consecutive patients who underwent cardiac surgery and were prospectively entered into our institutional database were selected. In this period, we recorded 168 SWC. At presentation, 16 patients were diagnosed with mediastinitis and were excluded from the study since they received surgical revision as first-line treatment. The 152 remaining patients had an SWD (incidence 2%) and constitute our study population. We identified 96 superficial SWD (63%) and 56 deep SWD (37%); overall, 77 (51%) were not infected and 75 (49%) infected. At our institute, the routine use of VAC therapy started in 2007; in the 'pre-VAC era' 107 patients were managed with conventional treatment (Group A), and thereafter, 45 patients received VAC treatment (Group B). General patient characteristics, risk factors for SWC and incidence of different types of SWD recorded in each group are summarized in Table 2 . The observed distribution of risk factors and types of SWD was significantly different in the two groups. In order to compare similar populations with similar comorbidities and equal incidence of SWD subtypes, propensity scores were calculated. Of the entire population, 59% of the patients (90 of 152) were perfectly matched for general characteristics, available risk factors and incidence of SWD subtypes, with an equal distribution of risk covariates (Table 3) .
Statistical analysis
Categorical variables were expressed as absolute frequency distribution ( percentage). All continuous variables were normally distributed (Shapiro-Wilk normality test) and were expressed as means ± 1 standard deviation. Categorical variables were com- See reference [7] . CT: computed tomography; MRI: magnetic resonance imaging.
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V. Tarzia et al. / Interactive CardioVascular and Thoracic Surgerypared by the χ 2 test or Fisher's exact test as appropriate. Student's t-test (for unpaired data) was used to compare continuous variables. Propensity score matching analysis was used to adjust for baseline characteristic differences between the two groups (one-to-one matching based on propensity scores). The propensity score was estimated by a logistic regression model for each patient. Matching using a calliper of width of 0.2, the standard deviation of the logit of the propensity score was performed. Variables used in the propensity analysis were age, sex, nature of cardiac procedure (according to cardiac pathology: ischaemic, valvular and others), congestive heart failure (defined as an ejection fraction of <30%), bilateral internal thoracic artery harvesting in coronary artery bypass graft surgery, severe chronic obstructive pulmonary disease according to The Society of Thoracic Surgeons scoring (defined as a history of emphysema, chronic bronchitis and bronchiectasis, requiring long-term use of bronchodilators or need for corticosteroid therapies), diabetes mellitus (defined as a history of diabetes regardless of the duration of disease or need for anti-diabetic agents), obesity (defined as body mass index of 30 and above), renal insufficiency (renal function was estimated by a serum creatinine level of ≥1.5 mg/dl), reintervention, urgency (due to the haemodynamic instability), surgical revision for bleeding and type of SWD. The propensity score matching generated a matched cohort in which the baseline prognostic variables were well balanced. Propensity c-statistic was 0.96. Comparison between groups' outcomes was carried out taking into consideration the matched nature of the propensity score-matched sample. In particular, paired t-tests were used for continuous variables and Mc Nemar test was used for binary (dichotomous) variables. Statistical findings were considered significant if the critical level was ≤5% (P ≤ 0.05). Statistical analysis was performed using the STATA software (Release 10.0 for Windows, StataCorp LP, College Station, TX, USA).
Costs definitions
Actual hospital costs were calculated, in the matched population, for every patient who was managed either with conventional treatment or with VAC therapy. Our cost-effectiveness analysis compared the direct costs ( patient care related) including the human resources cost. The following items for each procedure were considered: daily cost of the VAC therapy; cost of the use of the operating theatre; cost of a day of admission in hospital; daily cost of the intensive care unit (ICU). To calculate the total cost for each patient, we multiplied the unit cost of the various components of care by the documented use and then summed the product. Medical, nursing and technical staff salaries were considered in the total cost of the procedure for every patient.
RESULTS
In total, 45 patients for each group were matched, with similar incidence of SWD subtypes and balanced patient comorbidities, thus providing unbiased estimation of the effect of treatment (Table 3) . Five SWD-related deaths were recorded in Group A, while there were no deaths in Group B, representing a significantly higher mortality rate in the first group (11 vs 0%, P = 0.05). The ICU stay was slightly prolonged in Group A, although not statistically significant (9 ± 15 vs 5 ± 7 days, P = 0.07), while overall hospital stay was comparable (30 ± 22 vs 27 ± 14 days, P = 0.42). Mediastinitis (18 vs 2 patients, P < 0.0001) and sepsis (8 vs 2 patients, P = 0.04) were more frequent in Group A. Likewise, delayed SWD infection, defined as a sterile SWD that becomes infected during treatment, was more frequent in Group A (7 vs 1 patient(s), P = 0.05). Incidence of cardiac rupture was similar (3 vs 1 case(s), P = 0.61). Other complications, comprising bleeding, fistula formation and respiratory failure due to abnormal respiratory dynamics, were recorded in 7 patients in Group A and in 1 case in Group B (P = 0.05). Among patients managed with conventional treatment, 27 required the use of the operating theatre for a superficial surgical revision and 18 for a sternal surgical revision, while in the VAC therapy group, the same occurred in a significantly lower number of cases: 6 (P < 0.0001) and 9 (P = 0.03) patients, respectively. The mean duration of VAC treatment was 38 ± 27 days (median 34 days); 15 patients were discharged with VAC therapy and managed at the outpatient clinic. Organisms isolated from infected SWD were similar in the two groups, with a predominance of Gram-positive bacteria; the most common organism isolated was Staphylococcus aureus. Results of the matched population analysis are summarized in Table 4 .
Cost analysis
Considering the costs of ICU stay, hospital stay, treatment of complication and VAC therapy, the overall expenses were 1 399 788€ in Group A and 1 097 256€ in Group B; mean patient costs were 31 106€ and 24 383€, respectively ( Table 5 ). Most of the difference in cost between the two groups consisted of the costs related to the treatment of complications and prolonged ICU stay. The overall calculated saving was 302 532€ with a mean saving of 6723€ per patient.
DISCUSSION
SWD is a serious complication associated with a high mortality rate, especially in the setting of a mediastinitis, and with an increased cost of care [1, 2] . Our institutional management of sternal wound complications was surgical revision as first-line treatment for mediastinitis and open packing for superficial and deep SWD until 2007, when VAC therapy was introduced and became the gold standard for managing SWD.
VAC therapy was pioneered by Argenta and Morykwas in 1997; the beneficial effects of this technique on wound healing were attributed to a reduction in chronic oedema and increase in local blood flow, with enhanced formation of granulation tissue [6] . Wackenfors et al. [9] showed that VAC therapy induces a selective increase in blood flow in the peristernal soft and muscular tissue that is dependent on the negative pressure applied, with a greater response in subcutaneous rather than muscular tissue and maximal efficacy between −75 and −100 mmHg; they also demonstrated that wound fluid partial pressure of oxygen and lactate levels increased during treatment, further promoting wound healing. Recent studies highlighted the role of mechanical deformation induced by the VAC system as an important contributor to the effectiveness of negative-pressure therapy. Saxena et al. [10] observed micro-deformations in histological sections of VAC-treated wounds and, using a computational model, demonstrated that vacuumdependent strain induces cell stretching, eventually promoting cellular proliferation. Daigle et al. [11] attribute the efficacy of VAC therapy to macro-and micro-deformations in the wound tissue; they postulate that traction and superficial hypoperfusion induced by negative-pressure stimulate sprouting angiogenesis (via vascular endothelial growth factor gradient) and that cell stretching leads to differentiation (via transforming growth factor-β1 expression) of myofribroblasts, known to positively increase neovascularization, extracellular matrix deposition and wound contraction.
Several studies have shown encouraging clinical results of VAC therapy when used in the setting of mediastinitis [12] [13] [14] [15] [16] . These works have considered the use of VAC only in this particular type of SWC. Conversely, our study is the first to analyse the impact of the VAC therapy on all types of SWD (superficial, deep, infected and non-infected). From the outset, at our institution, VAC therapy has been used strictly according to the guidelines of the To evaluate the impact of VAC treatment on the outcomes of SWC, we have compared two groups: those treated in a traditional fashion (Group A) and those treated with VAC (Group B). The wounds we have analysed were superficial dehiscence, infected and non-infected, and deep SWD, infected and non-infected. In the deep SWD group, we have included all patients with sternal instability, without evidence of mediastinitis. In doing so, we have considered mediastinitis, which developed during the course of study, as a complication of treatment. In order to obtain two homogenous groups with comparable types of wounds and risk factors for sternal wound complications, we have adopted propensity matching.
Our study demonstrated that VAC therapy performs well in treating SWD compared with traditional treatment. VAC treatment was associated with lower rates of SWD-related mortality, sepsis and mediastinitis. It is our opinion that VAC achieves these outcomes by transforming an open wound to a closed environment, stimulating cellular proliferation and neoangiogenesis, increasing the blow flow to the wound and therefore circulation of antibiotics and immune cells, decreasing tissue oedema, increasing the delivery of nutritive substances and assisting with the removal of purulent and non-viable material. These factors all help to prevent worsening of the lesion and infective progress. Supporting this contention is the lower number of delayed sternal wound infections seen in the VAC group in our study, compared with the traditional group.
The mean ICU stay was reduced, although not significantly, in the VAC group, while the overall hospital stay was similar between the two groups. The first result could be attributable to a reduced incidence of complications; the second may be related to our VAC strategy: we consider VAC treatment as a bridge to complete wound closure by secondary intension instead of a bridge to surgical revision. This strategy inevitably leads to a prolonged mean duration of hospitalization, but permits us to minimize reintervention and operating theatre use, thus reducing expenses. Nevertheless, in selected cases, we were able to discharge patients with the VAC system in situ. The implementation of VAC therapy in a domiciliary setting increases mobilization and physical and emotional well-being of patients, improving patient comfort [12] .
Cost analysis showed that the majority of costs are due to a prolonged ICU stay and treatment of complications by either superficial or deep surgical revision in the operating theatre. Although the VAC itself is associated with a cost, the reduced complication rate actually results in a cost saving, totalling 305 523€ in this study or 6723€ per patient. This is the first described cost analysis of the use of VAC therapy reported in the literature.
In conclusion, VAC is associated with improved outcomes in the treatment of SWDs when compared with traditional therapy. VAC therapy reduces SWD-related mortality rate, incidence of complications (mediastinitis and sepsis) and incidence of delayed sternal infection. Our strategy allowed a significant reduction in the need for surgical revision in the operating theatre. In selected cases, VAC therapy could be implemented in an outpatient setting, increasing patient comfort through improved mobility and bio-psychosocial well-being. Furthermore, by means of reduced ICU stay and lower incidence of complications, VAC therapy is associated with a considerable cost reduction.
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APPENDIX. CONFERENCE DISCUSSION
Dr Datta: Right. My second question concerns the patient in Group B, whom you mentioned had a cardiac rupture. How did you manage that patient? Dr Carrozzini: Well, cardiac rupture is a serious condition. It is an emergency, and these patients received surgical revision. So the patient goes to the OR because we have right ventricular lesions. These are isolated cases, but they were very serious conditions. Dr Datta: Normally, when you change your VAC dressings, do the patients go to theatre? If, for example, the sternum is open and it is a deep sternal wound infection, how do you change the VAC pump? Are they changed in the operating theatre?
Dr Carrozzini: Do you mean the normal medication of the VAC therapy? Dr Datta: Changing the dressing, changing the sponge. Dr Carrozzini: Well, only if there is a complication such as mediastinitis or other complications such as fistulas, do we have to use the operating theatre. Otherwise, we do it in the ward.
Dr Datta: Even when the sternum is open, and the heart completely exposed?
Dr Carrozzini: Well, we do not have cases where the sternum is completely open because these conditions are mediastinitis. And we do not use VAC therapy to treat mediastinitis. We treat mediastinitis with surgical revision and closed irrigation.
Dr Datta: So you're telling me that in all your VAC therapy patients in Group B, all of them, the sternum was closed?
Dr Carrozzini: The sternum was closed. There might be some partial sternal instability, but not a clear reopening of the sternum.
Dr Datta: Okay, so some of your patients went home with the VAC therapy. Who managed them in the clinic? Do you have a separate wound clinic?
Dr Carrozzini: We managed them at the outpatient clinic, so the patients were managed by us.
Dr Datta: Okay. Can I go back to when I was asking you about the mediastinitis patients?
Dr Carrozzini: Yes. Dr Carrozzini: Well, the definition of mediastinitis we use is provided by the CDC certification; I can show you. You have to culture organisms directly from the mediastinal space or from the secretions from the mediastinal space. So your patient has to have an opening of the mediastinal space. And this is not the case in our series of patients.
Dr Uva: And you never tried to use the VAC system for mediastinitis? Is there a reason?
Dr Carrozzini: No. Dr Uva: You're afraid of sucking the heart? Dr Carrozzini: This is our policy. In the literature I described some series of patients treated with VAC therapy in the setting of mediastinitis. These patients show good results, but we only have a little evidence from these patients.
Dr M. Amorim (Braga, Portugal): I would like to ask you about this subgroup of patients with deep sternal infection. In this group of patients, in fact, the sternum is infected?
Dr Carrozzini: Yes. Dr Amorim: So did you open the sternum, did you remove the sternum, did you keep the patients on antibiotics or without antibiotics? Can you answer that?
Dr Carrozzini: Of course we use antibiotic therapy for all the patients with infected wound dehiscence, as we have isolated the organism, and we can perform a targeted antibiotic treatment. And we try to keep the sternum closed. And the VAC therapy, actually, allows us to stabilize the sternum. So we don't open the sternum. In fact, we don't remove the sternal wires, for example.
Dr Amorim: Okay. Dr Uva: But you don't rewire the sternum together, stabilize the wire? Dr Carrozzini: We rewire the sternum just in selected cases, but this is not the general situation.
Dr Uva: In which cases do you allow them to go home? Dr Carrozzini: I showed the criteria required before letting the patient go home; we need the patient to be clinically and haemodynamically stable.
Dr R. Van Valen (Rotterdam, Netherlands): I have a couple of questions and remarks. First of all, in our institution when there is a sternal instability, we say by definition you have a continuum with the mediastinum, so you have mediastinitis. And the second comment is what the previous speaker also said: the moment that the sternum is in sight and is unstable, you probably have an osteomyelitis, and I think you should at least rewire and irrigate. But I think the reason you are getting away with it is maybe by using the VAC, it's obliterating the open space. So first of all, I would like to hear your remarks about that.
Dr Carrozzini: As I said before, the VAC therapy stabilizes the sternum, but I don't agree with you when you say that the sternal instability is mediastinitis, because we haveDr Van Valen: But you have a positive culture. Dr Carrozzini: Sternal instability is a concept that is not so clear. I mean, you can have an opening, a clear opening of the sternum, and this is a sternal instability, but it is mediastinitis also. But our cases are patients that have just a partial, a little sternal instability, and you can't call this mediastinitis.
Dr Van Valen: I believe we can discuss some other time, but in the presence of a positive culture, you have a micro-organism in the wound, and you have mediastinitis.
Dr Carrozzini: When there was a deep sternal wound infection, there were positive swabs.
Dr Van Valen: And the second question is pretty much of the same order. Where you report in Group A three cardiac ruptures and in Group B one cardiac rupture, I would say in both groups, isn't this an ongoing mediastinitis that is treated improperly?
Dr Carrozzini: You can have a cardiac rupture not only in the setting of mediastinitis. I think that the cardiac rupture is mainly due to the partial sternal instability, that can lead to a lesion of the right ventricle when the chest is moving, but not to the infection itself.
Dr. Van Valen: In regards to that one, I think it's infection. But if you say it's not always infection, I agree with you. But shouldn't there be an extra argument to open the chest, to make the right ventricle free from adhesions and to rewire? I think it is a safer approach.
Dr Carrozzini: Yes, of course, when there wasDr Uva: I think we can discuss these things after the session. Dr A. Abousteit (Manchester, UK): This presentation emphasizes the role of VAC dressing, which is getting more and more involved in the treatment of sternal infection. I assume that in Group B, you have reached the stage to close the wound, not the sternum, to close the wound secondarily. What was the mean time, or the median time for that closure on VAC therapy, and was it comparable to that of conventional closure?
Dr Carrozzini: We didn't make this comparison, but we had a median time of 25 days for closure for the VAC therapy group. I don't have this data for the other group.
Dr Abousteit: Another quick question. It's just about the sternal instability. In our experience, I think of just taking out the sternal wires, and you can apply VAC to the mediastinum. You can provide some protection against drying of the ventricle; sometimes you can use a piece of membrane just to protect the heart. Adjusting the VAC dressing to minus 75 mmHg as an average, even on an open heart, gives a good result. It gives you a very good view of the sternum, if there is any osteoporosis, any infection going on, and you can add your debridement.
Dr. Carrozzini: But I repeat, we do not use the VAC therapy for this kind of treatment because the manufacturer stated that we can't use the VAC therapy, the foam, directly in contact with organs or vascular structures. So we simply do not use this kind of treatment.
Dr Abousteit: I think it is also used by the vascular surgeons when they have other problems.
Dr Carrozzini: I know, yes. Dr. A.Z. Apaydin (Izmir, Turkey): There was a paper from Japan which was presented this morning. It was about application of VAC for infected ascending aortic grafts. They really had very good results, so it is applicable to the open chest and for severe graft infection.
